Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 9, 2009
JNCI Journal of the National Cancer Institute 2009 101(12):846-847; doi:10.1093/jnci/djp171
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/12/846    most recent
djp171v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brower, V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brower, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

NEWS

How Well Do Angiogenesis Inhibitors Work? Biomarkers of Response Prove Elusive

Vicki Brower

The first 10% of the full text of this article appears below.

In 2007, the late Judah Folkman noted "a major obstacle" to the development of drugs targeted at angiogenesis, or new blood vessel growth, in tumors: the lack of noninvasive biomarkers for identifying patients most likely to respond to the drugs. Now, with three approved angiogenesis inhibitors (AIs) on the market—bevacizumab, sunitinib, and sorafenib—and hundreds of trials for others under way, the need for accurate, inexpensive, and noninvasive biomarkers has become even more pressing.

"Among researchers, there is a consensus that we need to step back and better understand how angiogenesis inhibitors work, and don’t work as well as we’d hoped," said Curzio Ruegg, M.D., professor and head of experimental oncology at Switzerland's University of Lausanne. "Better biomarkers should also help us answer the nagging question why AIs often improve . . . [Full Text of this Article]

Cytokine Markers

Platelet Proteome

Circulating Endothelial Cells


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?